Suppr超能文献

杜氏肌营养不良症和面肩肱型肌营养不良症的基因修饰因子

Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.

作者信息

Hightower Rylie M, Alexander Matthew S

机构信息

University of Alabama at Birmingham Graduate School of Biomedical Sciences, Birmingham, Alabama, USA.

Department of Pediatrics, Division of Neurology at Children's of Alabama and University of Alabama at Birmingham, MCLM 464 Box 96, 1918 University Boulevard Birmingham, Alabama, 35294, USA.

出版信息

Muscle Nerve. 2018 Jan;57(1):6-15. doi: 10.1002/mus.25953. Epub 2017 Sep 22.

Abstract

Muscular dystrophy is defined as the progressive wasting of skeletal muscles that is caused by inherited or spontaneous genetic mutations. Next-generation sequencing has greatly improved the accuracy and speed of diagnosis for different types of muscular dystrophy. Advancements in depth of coverage, convenience, and overall reduced cost have led to the identification of genetic modifiers that are responsible for phenotypic variability in affected patients. These genetic modifiers have been postulated to explain key differences in disease phenotypes, including age of loss of ambulation, steroid responsiveness, and the presence or absence of cardiac defects in patients with the same form of muscular dystrophy. This review highlights recent findings on genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies based on animal and clinical studies. These genetic modifiers hold great promise to be developed into novel therapeutic targets for the treatment of muscular dystrophies. Muscle Nerve 57: 6-15, 2018.

摘要

肌肉萎缩症被定义为由遗传或自发基因突变引起的骨骼肌进行性萎缩。新一代测序技术极大地提高了不同类型肌肉萎缩症诊断的准确性和速度。覆盖深度、便利性的提升以及总体成本的降低,使得人们能够识别出导致受影响患者表型变异的基因修饰因子。这些基因修饰因子被认为可以解释疾病表型的关键差异,包括行走能力丧失的年龄、对类固醇的反应性以及相同类型肌肉萎缩症患者是否存在心脏缺陷。本综述重点介绍了基于动物和临床研究在杜兴氏和面肩肱型肌肉萎缩症基因修饰因子方面的最新发现。这些基因修饰因子极有希望被开发成为治疗肌肉萎缩症的新型治疗靶点。《肌肉与神经》57: 6 - 15, 2018年。

相似文献

2
Therapeutic advances in muscular dystrophy.肌肉萎缩症的治疗进展。
Ann Neurol. 2013 Sep;74(3):404-11. doi: 10.1002/ana.23989.
3
The muscular dystrophies.肌肉萎缩症。
Semin Neurol. 2012 Jul;32(3):255-63. doi: 10.1055/s-0032-1329199. Epub 2012 Nov 1.
4
New therapies in muscular dystrophies.肌肉萎缩症的新疗法。
Neurol Sci. 2000;21(5 Suppl):S919-24. doi: 10.1007/s100720070004.
5
Outside in: The matrix as a modifier of muscular dystrophy.从外向内:基质作为肌肉萎缩症的修饰物。
Biochim Biophys Acta Mol Cell Res. 2017 Mar;1864(3):572-579. doi: 10.1016/j.bbamcr.2016.12.020. Epub 2016 Dec 21.
9
Muscular Dystrophies.肌肉萎缩症。
Clin Chest Med. 2018 Jun;39(2):377-389. doi: 10.1016/j.ccm.2018.01.004.
10
Immunobiology of Inherited Muscular Dystrophies.遗传性肌肉萎缩症的免疫生物学。
Compr Physiol. 2018 Sep 14;8(4):1313-1356. doi: 10.1002/cphy.c170052.

引用本文的文献

9
Targeted Gene Delivery: Where to Land.靶向基因递送:目的地何在。
Front Genome Ed. 2021 Jan 20;2:609650. doi: 10.3389/fgeed.2020.609650. eCollection 2020.

本文引用的文献

1
Pharmacological advances for treatment in Duchenne muscular dystrophy.药物治疗杜氏肌营养不良症的进展。
Curr Opin Pharmacol. 2017 Jun;34:36-48. doi: 10.1016/j.coph.2017.04.002. Epub 2017 May 6.
4
Eteplirsen in the treatment of Duchenne muscular dystrophy.依特普肽治疗杜氏肌营养不良症
Drug Des Devel Ther. 2017 Feb 28;11:533-545. doi: 10.2147/DDDT.S97635. eCollection 2017.
7
Regulation of muscle growth and regeneration by the immune system.免疫系统对肌肉生长和再生的调节。
Nat Rev Immunol. 2017 Mar;17(3):165-178. doi: 10.1038/nri.2016.150. Epub 2017 Feb 6.
9
Newborn Sequencing in Genomic Medicine and Public Health.基因组医学与公共卫生中的新生儿测序
Pediatrics. 2017 Feb;139(2). doi: 10.1542/peds.2016-2252. Epub 2017 Jan 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验